Genitourinary Syndrome of Menopause: Vaginal and Urinary Treatment Options

Related service: Hormone Replacement Therapy

Genitourinary syndrome of menopause, or GSM, describes vaginal, vulvar, sexual, and urinary symptoms caused by low-estrogen changes in the tissues of the vagina, vulva, urethra, and bladder. Symptoms can include dryness, burning, irritation, painful intercourse, recurrent urinary infections, urgency, and discomfort with examinations. Unlike hot flashes, GSM usually worsens without treatment. Low-dose vaginal estrogen is highly effective for many patients, but moisturizers, lubricants, vaginal DHEA, ospemifene, pelvic floor therapy, and other targeted care may also be appropriate.

Why the Term GSM Is Useful

Vaginal atrophy describes only part of the condition. Estrogen receptors are present throughout the vulvovaginal and lower urinary tract tissues, so patients may experience urinary symptoms without recognizing vaginal dryness. The broader GSM term helps connect recurrent UTIs, urethral burning, urgency, tissue fragility, and sexual pain to the same hormonal transition.

Symptoms can begin during perimenopause, become more prominent after natural or surgical menopause, or appear during breast-cancer treatment that suppresses estrogen. Severity varies and does not correlate perfectly with the visible examination. Some patients have significant discomfort with subtle findings, while others have marked tissue change and few complaints.

Typical Symptoms and Examination Findings

Patients may report dryness, rawness, itching, burning, spotting after intercourse, reduced lubrication, painful penetration, urinary urgency, frequency, dysuria, or recurrent culture-proven UTIs. Pain may lead to pelvic floor guarding, which adds muscle-related pain even after the tissue is treated.

Examination may show pale or thin tissue, loss of vaginal folds, reduced elasticity, narrowing, small fissures, urethral changes, or bleeding with contact. Infection, vulvar dermatoses, cervical disease, endometrial bleeding, pelvic floor pain, and bladder conditions can mimic GSM, so persistent symptoms should not be diagnosed from age alone.

Moisturizers and Lubricants

Vaginal moisturizers are used regularly, not only during intercourse, to improve hydration and comfort. Lubricants reduce friction during sexual activity. Water-based, silicone-based, and other formulations differ in duration, ingredients, condom compatibility, and irritation potential. Fragrance, warming agents, and high-osmolality products can worsen symptoms for some patients.

These nonhormonal options are reasonable first steps for mild symptoms or when a patient prefers to avoid medication. They do not reverse all tissue changes and may be inadequate for recurrent UTIs, significant pain, or moderate to severe dryness. Persistent symptoms should lead to a treatment discussion rather than repeated over-the-counter experimentation.

Low-Dose Vaginal Estrogen

Vaginal estrogen is available as cream, tablets or inserts, and a low-dose ring. A loading phase is often followed by maintenance dosing, depending on the product. It improves tissue thickness, elasticity, lubrication, pH, comfort, and many urinary symptoms. It also reduces recurrent UTIs in peri- and postmenopausal women when no contraindication is present.

Systemic absorption is low with standard low-dose products and generally decreases as tissue health improves. A progestogen is usually not required solely for standard low-dose vaginal estrogen, although unexplained or postmenopausal bleeding still requires evaluation. Vaginal estrogen treats local symptoms; it is not expected to control hot flashes or prevent bone loss.

Breast Cancer and Shared Decision-Making

Nonhormonal therapy is often tried first in patients with estrogen-dependent breast cancer history. When symptoms remain significant, low-dose vaginal estrogen may be considered through shared decision-making that includes the patient, gynecology clinician, and oncology team, particularly for patients taking an aromatase inhibitor. The decision weighs symptom burden, recurrence concerns, systemic exposure, treatment adherence, and alternatives.

Blanket reassurance and blanket prohibition are both inadequate. Product selection and dose matter, and the oncology regimen should not be stopped because of GSM symptoms without coordination. Severe urinary or sexual symptoms can meaningfully affect health and quality of life and deserve a documented plan.

Vaginal DHEA and Ospemifene

Prasterone is a vaginal DHEA insert approved for moderate to severe pain with intercourse due to menopause. Ospemifene is an oral selective estrogen receptor modulator approved for moderate to severe dyspareunia and vaginal dryness. Each has contraindications, interactions, adverse effects, and cancer-history considerations that differ from low-dose vaginal estrogen.

These options may fit patients who do not respond to moisturizers or prefer a different route, but they are not automatically safer for every high-risk patient. Cost and insurance coverage also influence practicality. Treatment response should be reassessed after a defined interval.

Pelvic Floor and Sexual Pain Treatment

When pain has caused guarding, pelvic floor physical therapy can improve muscle relaxation, coordination, scar sensitivity, and graded return to penetration. Dilators may be used with guidance for narrowing or pain. Treating tissue alone may not resolve long-standing muscle and nervous-system responses.

Sexual concerns may also involve desire, arousal, relationship factors, medication effects, and vulvar or pelvic disease. GSM treatment improves comfort but should not be presented as a complete treatment for every sexual concern.

Energy-Based Vaginal Devices

Vaginal laser and radiofrequency devices are marketed for dryness, urinary symptoms, or tissue rejuvenation. Evidence quality and durability are more limited than for approved vaginal estrogen, prasterone, or ospemifene, and energy-based devices are not FDA approved specifically to treat GSM. Potential harms include burns, scarring, pain, painful intercourse, and chronic injury. Patients should receive clear counseling about regulatory status, cost, uncertainty, and established alternatives.

When Symptoms Need Prompt Evaluation

Postmenopausal bleeding, a vulvar ulcer or mass, persistent focal pain, foul discharge, fever, visible blood in urine, inability to urinate, or recurrent urinary symptoms without culture confirmation requires evaluation. New bleeding should not be assumed to be a harmless effect of atrophy or vaginal estrogen.

Frequently Asked Questions

Is vaginal estrogen the same as systemic hormone therapy?

No. Low-dose vaginal products act primarily in local tissues and do not reliably treat hot flashes. Systemic exposure is much lower than with oral or transdermal estrogen.

Do I need progesterone with vaginal estrogen?

A progestogen is generally not required with standard low-dose local therapy. Any postmenopausal bleeding still requires evaluation.

Can vaginal estrogen prevent recurrent UTIs?

Yes. It is recommended for many peri- and postmenopausal patients with recurrent culture-proven UTIs when no contraindication is present.

How long is treatment needed?

GSM is chronic and often returns when treatment stops. Long-term maintenance is common, with periodic review of benefit, symptoms, and any bleeding.

Can laser replace estrogen?

It should not be presented as an equivalent established therapy. Evidence and regulatory status differ, and potential device risks require careful counseling.

The Bottom Line

Genitourinary Syndrome of Menopause is best approached with individualized assessment rather than a one-size-fits-all plan. A visit can clarify what evaluation or treatment fits your symptoms, history, and goals.

Schedule a Visit

Complete Healthcare offers individualized menopause and hormone care counseling for patients in Richland and the Tri-Cities. Call 509-392-6700 to schedule a menopause visit.

Complete Healthcare, Richland, WA

Kortney Jones, ARNP

Women’s Health and Wellness Care in Richland, WA